Naloxone Market Explore Future Growth by Global Top Players Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar, Inc., INSYS Therapeutics, Inc., Kaleo, Inc., and Kern Pharma, S.L.

Naloxone is an opioid antagonist used to counter the effects of opioid overdose, such as morphine and heroine. Naloxone is indicated for use in opioid overdose to counteract life-threatening depression of the central nervous system and respiratory system, allowing an overdose victim to breathe normally. Naloxone is non-scheduled prescription medication, which in most cases, is administrated by emergency response personnel or minimally trained personnel, and is thus ideal for treating overdose in people who are prescribed opioid pain medication. Naloxone can be administrated through parenteral route, by injecting in the muscle or vein.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1804

Market Dynamics -

Increasing launches and approval of new naloxone products in the market is expected to drive the global naloxone market growth over the forecast period. In October, 2016 Health Canada approved Narcan Nasal Spray 4 mg for non-prescription, community use in Canada

Rising prevalence of opioid overdose in key regions such as North America, and Europe is expected to drive demand for naloxone products and drive the naloxone market growth in the near future. For instance, according to the data published by European Monitoring Center for Drugs and Drug Addiction (EMCDDA), in 2016, around 150,943 high-risk opioid users were reported in Germany and around 330,445 were reported in the U.K.

Furthermore, initiatives by various government and private organizations to increase access of naloxone product among the population is also expected to drive market growth. For instance, in 2015, Kaleo, Inc. partnered with the Clinton Foundation and provided bulk discounts on its EVZIO to various college universities and public safety organizations.

Frequent launches and approvals of novel naloxone products is expected to fuel the global naloxone market growth

Increasing launches and approval of novel naloxone products by various regulatory bodies is expected to be a major factor aiding in growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In 2016, Mylan N.V. launched its naloxone hydrochloride injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. It is therapeutically equivalent to the naloxone hydrochloride injection 0.4 mg/mL, of Hospira Inc. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose.

The Global Naloxone Market Size Was Valued At Us$ 310.2 Mn In 2017, And Is Expected To Witness A Cagr Of 11.4% Over The Forecast Period (2018 – 2026).

Increasing Drug Abuse In Key Regions Is Expected To Increase Demand For Its Treatment Drugs

Increasing cases of opioid overdose is expected to increase demand for naloxone products during emergency treatments which in turn will positively drive the global naloxone market growth. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2016, around 11.5 million people misuse prescription drugs and around 948,000 people use heroin. According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.

Regulatory Scenario -

In 2016, Therapeutic Goods Administration (TGA) placed naloxone on Schedule 3 when used for the treatment of opioid overdose, thus allowing the over-the-counter (OTC) purchase of naloxone in Australia.

In Europe, many countries allow take-home naloxone due to high rate of opioid overdose in this region. Currently, take-home naloxone programs exists in seven European countries— Denmark, Estonia, Germany, Italy, Norway, Spain, and the U.K. (EMCDDA, 2015c).

According to the data published by Regulatory Affairs Professional Society, naloxone is still not approved by the U.S. FDA as an over-the-counter (OTC) drug. However, some organizations such as Walgreens pharmacies are providing naloxone products over-the-counter in over 5,800 of its 8,200 stores to increase the access of naloxone.

Naloxone Market Key Players -

Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

Detailed Segmentation:

Global Naloxone Market, By Strength:
- 0.4 mg/ml
- 1mg/ml
- 0.4mg/0.4ml
- 4mg/0.1ml and Others

Global Naloxone Market, By Drug Type:
- Intranasal
- Intramuscular/Subcutaneous
- Intravenous

Global Naloxone Market, By Distribution Channel:
- Hospitals
- Clinics
- Retail Pharmacies
- Online Pharmacies
- Others

Global Naloxone Market, By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa

Request For Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/1804

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.